Clinical Trials Update from NCI, July 25, 2017

Clinical Trials Update from NCI, July 25, 2017

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
		NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers Patient recruitment began July 24 for this nationwide trial that will explore whether targeted therapies can be effective for children and adolescents with solid tumors that harbor specific genetic mutations and have progressed during or after standard therapy.
Extensive Lymph Node Surgery Does Not Increase Survival in Melanoma New results from a large international clinical trial suggest a conservative approach to lymph node removal surgery may be best for people with melanoma that has spread to one or a small number of nearby lymph nodes.
		Two-Drug Combination Approved for Lung Cancers with BRAF Mutations A pair of phase 2 clinical trials support the Food and Drug Administration’s approval of dabrafenib (Tafinlar®) and trametinib (Mekinist®) in combination for the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.
Find NCI-Supported Clinical Trials Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
Clinical Trials Information for Patients and Caregivers
Patient Safety in Clinical Trials Federal rules help ensure the safety of people who take part in clinical trials. Learn how these rules are carried out.
Informed Consent Learn about informed consent and why it is essential to protecting the safety of people who take part in clinical trials.
Children’s Assent Children cannot legally consent to take part in a trial, but they can take part in making the decision. This page explains how children’s assent works
NCI-Supported Clinical Trials that Are Recruiting Patients
Pembrolizumab in Treating Patients with Recurrent or Metastatic Medullary Thyroid Cancer This phase 2 trial studies how well pembrolizumab works in treating patients with medullary thyroid cancer that has come back or spread to other places in the body.
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors This phase 1 trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors.
Anetumab Ravtansine in Treating Patients with Mesothelin Expressing Stage IIIB-IV Lung Cancer That Cannot Be Removed by Surgery This phase 1/2 trial studies the side effects and best dose of anetumab ravtansine and to see how well it works in treating patients with mesothelin expressing stage IIIB-IV lung cancer that cannot be removed by surgery.